Clostridium difficile infection (CDI) is the leading cause of antibiotic-associated nosocomial diarrhea. Recent studies have reported contradictory evidence of hypovitaminosis D as a novel risk factor for CDI; therefore, the current meta-analysis was conducted to examine the association between 25-hydroxyvitamin D (25[OH]D) concentrations and CDI. The results of the pooled estimates reveal a lower mean concentration of 25(OH)D in patients with CDI and an increased odds of severe CDI in patients with a lower 25(OH)D status.
Introduction
Clostridium difficile is a Gram-positive, spore-forming anaerobic bacillus, and worldwide it is the main cause of infectious diarrhea in hospitalized patients. The incidence and severity of C difficile infection (CDI) has increased in the past decades mainly due to the emergence of hypervirulent strains. 1 It is estimated that the additional CDI attributable length of stay in acute care facilities ranges from 2.8-6.4 days with an estimated cost per CDI case of up to US$15,397. 2 The economic burden to the US healthcare system attributable to CDI in 2008 was estimated at US$4.8 billion. 3 Traditionally, CDI has been associated with exposure to antimicrobials and gastric acid suppressant medications; however, a recent study has reported an association between higher concentrations of 25-hydroxyvitamin D (25[OH]D) and reduction in risk of CDI in patients with inflammatory bowel disease. 4 Furthermore, Abdelfatah et al 5 found a protective effect against severe cases of CDI in patients with concentrations of 25(OH)D >20 ng/mL. In contrast, van der Wilden et al 6 did not find an association between 25(OH)D concentrations and CDI severity.
Given the heavy burden on health systems imposed by CDI and the current contradictory evidence around 25(OH)D and CDI, a meta-analysis was conducted to assess the impact of 25(OH)D status on CDI.
Methods
A systematic review/meta-analysis (secondary analysis of deidentified published data) was conducted, and thus ethics committee approval and informed consent were not required. 
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Search Strategy and Eligibility Criteria
A systematic search with no language restrictions was undertaken in 3 medical and life sciences databases (PubMed, Embase, and Web of Sciences) from their inception to August 2015. Search terms included were Clostridium difficile and vitamin D; the specific keywords and connectors for each database are listed in the supplementary material.
The inclusion of studies was restricted to published (fulltext or conference abstracts) epidemiological studies in humans that reported concentrations of 25(OH)D in an extractable format. The studies were included if they reported mean 25(OH) D concentrations or data around the CDI-related outcomes of severity or recurrence. Studies that reported findings in animal models were excluded. No exclusion criteria were considered for indirect methods to detect CDI cases such as International Classification of Diseases (ICD) codes, as these have proven to be highly specific for CDI. 7 Similarly, no restrictions about CDI severity scores were considered as most score indices have a good sensitivity and specificity. 8 
Study Selection and Data Extraction
Two researchers (L.F.-K. and K.W.) independently assessed all the citations by titles and abstracts followed by a full-text review of all potentially relevant studies. Data from the included studies were then independently extracted in a spreadsheet by the same 2 researchers. The recorded fields included study identifiers (authors, publication year), study characteristics (design, setting, inclusion criteria, sample size), and mean 25(OH)D concentrations and outcome measurement (CDI, CDI severity, CDI recurrence). 25(OH)D status of "lower" or "higher" was defined based on concentrations <20 ng/mL and ≥20ng/mL. 9 The extracted data were then cross-checked by the 2 researchers, and any discrepancies during the selection of studies or data extraction were resolved through discussion and consensus.
Statistical Analyses
The effect sizes for the difference in mean 25(OH)D concentrations across CDI diagnosis status and the odds ratios (ORs) for the association between 25(OH)D status and CDI severity or CDI recurrence were pooled using the inverse variance heterogeneity (IVhet) model. 10 Statistical heterogeneity among studies was assessed by both the Cochran's Q and I 2 index; heterogeneity was defined as low (I 2 < 25%), moderate (I 2 = 26%-50%), and high (I 2 > 50%). While I 2 is the percentage of variability that is due to between-study heterogeneity, 1 -I 2 is the percentage of variability that is due to sampling error. The latter is affected by study size; thus, when the studies become very large, the sampling error tends to 0 and I 2 tends to 1.
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Such heterogeneity may not be clinically relevant, and studies with relatively large I 2 in this situation may still be usefully pooled if other measures such as Q or τ 2 remain relatively small and clinically relevant heterogeneity is unlikely to be present. In addition, the model used to pool effect sizes (IVhet model) takes account of the uncertainty due to heterogeneity and adjusts the confidence interval (CI) adequately, 10 which does not happen with the random-effects model, thus again justifying pooling in the face of heterogeneity documented using the I 2 index. The meta-analyses were conducted using MetaXL v3.0 (EpiGear International, Sunrise Beach, Australia).
Results
Yield of Search Strategy
The search strategy identified 147 records in the 3 databases after removal of duplicate records. Of these, 121 studies were excluded based on a review of title and abstract. Full texts of the remaining 26 studies were reviewed, and 8 articles were selected and included in the final analyses (see Figure 1 ).
Characteristics of Included Studies
All the studies were conducted in healthcare settings in the United States. Half of the studies were conducted prospectively, 4, 6, 12, 13 one of which only enrolled patients with inflammatory bowel disease. 4 Among the included studies, 3 reported 25(OH)D concentrations by C difficile diagnosis outcome (infected vs noninfected). 4, 14, 15 Three studies 5, 6, 16 assessed the association between 25(OH)D status (<20 ng/mL vs ≥20 ng/ mL) and CDI severity (mild vs severe). Finally, 4 studies 5, 12, 13, 16 examined the association between 25(OH)D status (<20 ng/mL vs ≥20 ng/mL) and CDI recurrence (see Table 1 ).
Quantitative Synthesis
The pooled mean difference in 25(OH)D concentrations between patients with and without CDI was −3.54 ng/mL (95% CI, −6.89 to −0.39 ng/mL), and thus mean 25 
Discussion
Our findings provide some evidence that lower mean concentrations of 25(OH)D were present in patients diagnosed with CDI and that CDI severity was associated with a lower 25(OH) status. Paradoxically, pooled estimates did not reveal an association between 25(OH)D concentrations and CDI recurrence. One possible explanation for this finding may be differences in the duration of follow-up time used by the researchers. For instance, when CDI recurrence was defined as "within 30 days," Arramraju et al 12 and Wang et al 13 found a significant association between lower 25(OH)D status and recurrence; however, when CDI recurrence was evaluated in a longer follow-up period of 56 and 90 days, Abdelfatah et al 5 and Wong et al 16 did not find an association. We must point out, however, that study considerations may have had a role in this discrepancy. For example, Wang et al 13 categorized patients who died as a "nonresolution" of CDI, which may have led to an overestimation of failure to resolve C difficile, since the exact cause of mortality in each patient was unknown. In addition, other factors such as exposure to certain antibiotics (cephalosporins, aminopenicillins, and clindamycin), proton pump inhibitor use, increased patient age, and number of previous admissions 17 may have affected the CDI recurrence pooled estimate since controlling for these covariates was not possible.
The findings align with those reported by Youssef and colleagues, 18 who described an association between 25(OH)D deficiency (<20 ng/mL) and other hospital-associated infections such as bacterial sepsis and methicillin-resistant Staphylococcus aureus colonization. The findings are also in line with those hypothesized beneficial effects of vitamin D supplementation on the reduction of surgical site infections as well as catheter-associated urinary tract infections. 18 In addition, ecological studies have reported an inverse relationship between ultraviolet B ray exposure (a major promotor of vitamin D synthesis) and CDI mortality 19 or influenza cases complicated by pneumonia. 20 Our findings therefore add to the growing body of evidence identifying a potential role of lower 25(OH)D status in infectious disease susceptibility.
Although the mechanisms by which 25(OH)D may act as an immunomodulator for CDI are not fully understood, possible explanations are available. Vitamin D plays a vital role in innate (nonspecific) immune response through the stimulation of nitric oxide, 21 cathelicidins, 22 and β-defensin 2 23 production in macrophage lysosomes and epithelial cells. Furthermore, vitamin D also modulates cell-mediated immunity via the differentiation of naive T cells into regulatory CD4 + T lymphocytes. 24 The immunomodulatory activity of vitamin D has also been described in patients with autoimmune disease (multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis) in which supplementation of vitamin D resulted in a reduction in disease severity. [25] [26] [27] This is the first meta-analysis that examines a potentially new risk factor for CDI; however, several limitations were noted that warrant future research. First, the strains of C difficile ribotypes infecting individuals differ by country/region, and certain C difficile ribotypes are associated with different outcomes (eg, recurrence, severity, mortality). The studies included here were all conducted in the Northeast or Midwest regions of the United States, and C difficile ribotypes were not taken into account. Second, due to the limited number of studies identified, subgroup analysis by the source of CDI (healthcare vs community acquired) was not possible. Finally, no studies were identified that examined the effect of 25(OH)D in asymptomatic C difficile colonized individuals. Given that this group of people are a potential source of CDI and may contribute to the transmission of the pathogen, further epidemiological studies are required to investigate the role of 25(OH)D in this particular group of people. In view of the safety of vitamin D supplements and their potential to favorably influence the outcome or burden of CDI, we recommend the implementation of randomized controlled trials to examine the effect of vitamin D supplementation in the reduction of CDI occurrence and CDI severity. 
